InsidersTradesSigma
Track the Bionano Genomics, Inc. stock price and the full management transaction log of the company, a listed issuer based in United States. Shares are listed on the US market, under the oversight of SEC (Form 4). Operating in the Healthcare & Pharma sector, Bionano Genomics, Inc. has published 54 public disclosures. Market capitalisation: €13.9m. The latest transaction was disclosed on 21 August 2026 (Acquisition). Among the most active insiders: OLDAKOWSKI MARK. All data is openly available.
54
Insider Decl.
n/a
Thresholds
€113,081
6 ops.
Buy Volume
n/a
n/a
Sell Volume
33Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 28,288 of 29,063 companies
11.7
score / 100
Value1
Quality23
FCF yld-114%
Earn yld-184%
EV/EBITDA·
ROE-84%
Gross mgn46%
Net mgn-93%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 21 August 2026
Declarations54 total
4,000 shares@ US$1.215Common StockSEC:0001746822-26-000003:0
Canonical exit: 19 Nov 2026 (T+90)
7 shares@ US$1.300.0001% mcap14.9% of flowCommon StockSEC:0002036536-26-000006:0
27 shares@ US$1.300.0003% mcap0.0% of flowCommon StockSEC:0001745566-26-000006:0
24 shares@ US$1.300.0002% mcap1.0% of flowCommon StockSEC:0001821605-26-000006:0
24 shares@ US$1.300.0002% mcap5.0% of flowCommon StockSEC:0001967837-26-000006:0
3 shares@ US$1.105.0% of flowCommon StockSEC:0002036536-26-000004:0
6 shares@ US$1.100.9% of flowCommon StockSEC:0001967837-26-000004:0
18 shares@ US$1.100.6% of flowCommon StockSEC:0001821605-26-000004:0
20 shares@ US$1.100.0% of flowCommon StockSEC:0001745566-26-000004:0
51 shares@ US$1.100.0% of flowCommon StockSEC:0001579988-26-000004:0
59 shares@ US$4.060.2% of flowCommon StockSEC:0001745566-25-000005:0
51 shares@ US$4.065.9% of flowCommon StockSEC:0001821605-25-000006:0
59 shares@ US$4.060.2% of flowCommon StockSEC:0001745566-25-000007:0
7 shares@ US$3.6943.3% of flowCommon StockSEC:0001411690-25-000055:0
27 shares@ US$3.690.1% of flowCommon StockSEC:0001411690-25-000056:0
24 shares@ US$3.692.8% of flowCommon StockSEC:0001411690-25-000054:0
25 shares@ US$3.6913.1% of flowCommon StockSEC:0001411690-25-000052:0
75 shares@ US$3.690.2% of flowCommon StockSEC:0001411690-25-000053:0
198 shares@ US$3.470.5% of flowCommon StockSEC:0001411690-25-000028:0
20 shares@ US$5.730.1% of flowCommon StockSEC:0001411690-25-000019:0
4 shares@ US$5.7341.8% of flowCommon StockSEC:0001411690-25-000015:0
18 shares@ US$5.733.6% of flowCommon StockSEC:0001411690-25-000016:0
51 shares@ US$5.730.2% of flowCommon StockSEC:0001411690-25-000017:0
6 shares@ US$5.736.1% of flowCommon StockSEC:0001411690-25-000018:0
3,075 shares@ US$0.4848.8% of flowCommon StockSEC:0001411690-24-000052:0
25 of 54 declarations
关于 Bionano Genomics, Inc.
Bionano Genomics, Inc. 是一家总部位于美国加利福尼亚州圣迭戈的生命科学和基因组学技术公司，在纳斯达克市场上市。该公司专注于光学基因组图谱（OGM），这是一种基因组分析方法，旨在检测传统测序工作流程难以表征的结构变异和其他大规模 DNA 变化。公司资料显示，Bionano 最初于 2003 年成立，名为 BioNanomatrix，后来随着其商业足迹和产品组合的扩展，演变为 Bionano Genomics。（[ir.bionano.com](https://ir.bionano.com/static-files/0a1c1d2c-f90c-407b-b436-a0ba28e49e12?utm_source=openai)) 公司的核心业务围绕一个集成的基因组学平台构建，该平台结合了仪器、耗材、软件和实验室服务。其旗舰产品 Saphyr 系统用于生成高分辨率基因组图谱，而相邻的软件工具则支持细胞遗传学和分子病理学中的数据解释。Bionano 还为希望获取 OGM 生成数据但不在内部部署平台的客户提供实验室服务。这创造了一个相对广泛的商业模式：Bionano 不仅仅是仪器供应商，还是一个涵盖样本处理、分析和解释的工作流程提供商。（[ir.bionano.com](https://ir.bionano.com/static-files/43cc3af0-d812-4743-b2b0-dc12def33d44?utm_source=openai)) 从竞争角度来看，Bionano 在基因组学的一个专业但具有战略重要性的领域运营，该领域专注于研究、临床细胞遗传学以及选定的肿瘤学和罕见疾病应用。其主要区别在于 OGM 能够捕获大型结构变异和复杂基因组重排，这些变异和重排通常被标准方法遗漏或不完全解析。从这个意义上说，Bionano 将自己定位为传统基因组检测工作流程的替代品或补充。（[bionano.com](https://bionano.com/?utm_source=openai)) 近期发展表明公司正处于重组模式。在其 2024 年更新中，Bionano 表示已大幅削减成本，以改善其盈利路径，同时继续推进 OGM 和软件的采用。公司还报告称，截至 2024 年底，其 OGM 装机量有所增长。最近的披露表明，公司战略重点是其 OGM 解决方案的常规用户，并在美国和国际市场实现更广泛的采用。对于投资者而言，Bionano 仍然是一家高度专业化的纳斯达克上市基因组学公司，拥有差异化的技术平台，但也面临着小型生物技术和生命科学仪器公司典型的执行和融资压力。（[ir.bionano.com](https://ir.bionano.com/news-releases/news-release-details/bionano-reports-preliminary-fourth-quarter-and-full-year-2024/?utm_source=openai))
